Viatris and Biocon's Semglee (biosimilar- insulin glargine) Receive the US FDA's Approval as the First Interchangeable Biosimilar for Diabetes
Shots: The US FDA has app...
Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021
Shots: The P-III study ev...
Viatris' Interchangeable Insulin Biosimilar Listed on Express Scripts Largest Formulary in the US
Shots: Viatris' interchan...
Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D
Shots: The company comple...
